Benfotiamine is a fat-soluble thiamine (B1) derivative with 5x greater bioavailability than regular thiamine. It blocks AGE formation (advanced glycation end products) and reduces diabetic neuropathy symptoms. A 2008 RCT found 600mg/day benfotiamine significantly reduced neuropathic pain in diabetic patients. Also prevents high-glucose damage to endothelial cells (AGE pathway blockade). Dose: 150-600mg/day. Distinct from sulbutiamine (which crosses BBB). Benfotiamine does NOT cross BBB — peripheral benefits only. --- *Reviewed by the Dose AI Research Team and Clinical Advisory Board* *Last updated: 2026-04-06*
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.